Fast-paced and focused on emerging science and treatment techniques, Turning the Tide is an interactive activity designed to sharpen participants’ understanding of psoriasis, psoriatic arthritis, and atopic dermatitis and equip them with forward-thinking patient-centered communication strategies. Through a combination of medical animation, TED Talks-style presentations, a clinical case study, and a discussion of patient-provider shared decision making, learners will explore disease pathophysiology, mechanisms of action of targeted therapies, evidence-based treatment recommendations, and use of decision aids. Learners will be provided access to slides and additional resources.
The target audience is dermatologists. Other healthcare professionals, including rheumatologists, physician assistants, and nurse practitioners who treat patients with psoriasis, PsA, and AD, may benefit from participation in this educational activity.
Upon completion of the activity, participants should be able to:
Describe current models explaining pathophysiology of psoriasis and atopic dermatitis.
Identify mechanisms of action and effectiveness of existing and emerging targeted treatments for psoriasis and atopic dermatitis.
Discuss evolving treatment strategies and safety of treatments for psoriasis, psoriatic arthritis, and atopic dermatitis.
Engage patients with psoriatic disease or atopic dermatitis in shared decision making regarding goals of treatment, development of treatment plan, and treatment modification.
There is no fee for this educational activity.
Conflict Of Interest Disclosure Policy
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Bruce Strober, MD, PhD Professor Department of Dermatology University of Connecticut Health Center Farmington, Connecticut
Dr. Strober discloses the following: Consultant (honoraria): AbbVie, Almirall, Amgen, Arena, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, GlaxoSmithKline, Janssen, LEO Pharma, Lilly, Medac, Meiji Seika Pharma, Menlo Therapeutics, Novartis, Ortho Dermatologics/Valeant, Pfizer, Regeneron, Sanofi Genzyme, Sebela Pharmaceuticals, Sitris, Sun Pharma, UCB Investigator (no direct payments made to Bruce Strober, MD, PhD): AbbVie, Boehringer Ingelheim, Celgene, Galderma, GlaxoSmithKline, Janssen, Lilly, Merck, Pfizer, Sienna Biopharmaceuticals Scientific Director (consulting fee): Corrona/NPF Psoriasis Registry Grant support for Fellowship Program (payments to the University of Connecticut): AbbVie, Janssen, National Psoriasis Foundation
Richard Martin, MD, MA Professor of Medicine and Rhematology Michigan State University College of Human Medicine East Lansing, Michigan
Dr. Martin discloses the following: Contracted Research: AbbVie, Amgen, AstraZeneca, Lilly, Cytor
April W. Armstrong, MD, MPH Consultant: Novartis, Sanofi, Regeneron, Pfizer, Celgene, Modernizing Medicine, AbbVie, Lilly, Merck, and Janssen Speaker and researcher: Lilly, AbbVie, and Janssen
Accredited Provider Disclosure
Forefront Collaborative Christine Tebben, has nothing to disclose in regards to financial relationship(s) with commercial interests. Marianna Shershneva, MD, PhD, has nothing to disclose in regards to financial relationship(s) with commercial interests.
AMA PRA Category 1 Credit(s)TM
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Forefront Collaborative designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.